The phase I/II trial (CheckMate 040) was the first to exhibit the efficacy of a CTLA-4 inhibitor (ipilimumab) in combination with a PD-1 inhibitor (nivolumab) in patients with advanced HCC. The gene discussed is CTLA4; the disease is hepatocellular carcinoma.